Published May 4, 2026, 6:45 AM ET · Updated 6 months ago · 1 source
Immune System Biotech Odyssey Seeks $238.3 Million in US IPO
bloomberg
·
Original Report
INFERY
Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to raise $238.3 million in an initial public offering.